Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

British System Highlights Cost-Effectiveness Concerns As Part Of U.S. Overhaul Effort
While Congress recently approved funds to study the cost-effectiveness of certain treatments, some are concerned that such research could lead to rationing of health care or that treatments deemed less effective will not be adequately covered, the AP/Washington Post reports. Those concerned often cite Great Britain"s National Institute for Health and Clinical Excellence, which determines which medical treatments will be covered based on cost-effectiveness. One of the criteria used by NICE to determine a treatment"s cost-effectiveness is how much each additional year of life will cost the government, which the agency has capped at about $47,000 per year of life in most cases (Cheng, AP/Washington Post, 5/26).
generic viagra online
Health Care Ads Leave Washington, Follow Lawmakers Home During Break
Roll Call reports that "several major industry stakeholders" will be "noticeably absent from the advertising airwaves over the July Fourth recess. Though they will continue to keep in touch with Members through meetings and grass roots, AARP, the American Medical Association, America"s Health Insurance Plans, the Federation of American Hospitals and AdvaMed all say they are sitting out this recess when it comes to advertising campaigns." Senate Finance Chairman Max Baucus, D-Mont., and White House aides have "warned that any groups that run ads attacking reform efforts before the bills have been crafted would lose their seats at the bargaining table," but the "advocacy ad floodgates" may "open shortly." Until then, "groups are working in a lower-profile way to get their messages across to Members," such as planning in-district meetings with Members and activating grassroots networks.
News of the day
Prevention Magazine™ Says "Take SunPill To Boost UV Sun Protection"
XenaCare Holdings Inc. (OTCBB:XCHO), a healthcare company specializing in the branding, retailing and internet distribution of consumer products, has announced today that in the July 2009 issue of Prevention Magazine™ an article written by Roopoka Malhorta which is about Ageless Summer Beauty - 21 fast, easy ways to look young - and stay that way - this summer and beyond states as their #1 choice was to "Try a Sun Protection pill" they further stated "ò€¦boost your UV protection by taking an antioxidant supplement such as SunPill ($20 for a month"s supply; available at http://www.sunpill.com)." According to Frank Rizzo, president of XenaCare, the SunPill can also be purchased at Walgreens, Rite-Aid, Amazon.com, Drugstore.com, CVS.com, Target.com and various other major retailers.
Health Insurance

BioElectronics Prepares For General Surgical Recovery FDA 510(k) Premarketing Application Submission

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced the Company is currently preparing an application for 510(k) premarket notification for submission to the Food and Drug Administration (FDA) for general surgical recovery. The filing will request an indication for the adjunct of use in palliative treatment of postoperative edema and pain in superficial soft tissue. "There is overwhelming clinical data demonstrating the application of PEMF therapy significantly reduces postsurgical edema (swelling), pain and speeds healing. There are currently several devices cleared for this indication of use, but these devices are very large, expensive and are in no way portable, so they are neither practical nor marketable for surgical recovery. BioElectronics" portable version of PEMF, for which we recently were granted a patent, is very different. Our biomedical engineers have been able to shrink PEMF technology into a wearable patch that can be applied directly over the site of surgery," commented Andrew Whelan, CEO of BioElectronics. "Many surgeons are already using our products as an adjunctive therapy in the post-operative environment to speed healing and to significantly reduce, or in many cases, completely eliminate the use of narcotics, Tylenol® or acetaminophen, and NSAIDs to control surgical related pain within their patient populations." BioElectronics Corp."s RecoveryRX™ devices have already received FDA clearance for the treatment of edema following blepharoplasty, a common plastic surgery procedure. Gaining this additional FDA indication will allow the Company to market its products for use in the general surgical market, which consists of hundreds of thousands of procedures performed each year in both the ambulatory and outpatient environments. The Company recently filed with FDA for clearance to market its Allay™ Menstrual Pain Relief Patch product and is currently in process of completing numerous clinical trials designed to support additional marketing clearance applications with FDA. BioElectronics Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009